Potential Onco-Suppressive Role of miR122 and miR144 in Uveal Melanoma through ADAM10 and C-Met Inhibition by Amaro, Adriana et al.
cancers
Article
Potential Onco-Suppressive Role of miR122
and miR144 in Uveal Melanoma through ADAM10
and C-Met Inhibition
Adriana Amaro 1,† , Michela Croce 1,† , Silvano Ferrini 1, Gaia Barisione 1, Marina Gualco 2,
Patrizia Perri 3 , Ulrich Pfeffer 1 , Martine J. Jager 4 , Sarah E. Coupland 5,6 , Carlo Mosci 7,
Gilberto Filaci 1,8, Marina Fabbi 1 , Paola Queirolo 9 and Rosaria Gangemi 1,*
1 IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy; adriana.amaro@hsanmartino.it (A.A.);
michela.croce@hsanmartino.it (M.C.); silva.ferrini@gmail.com (S.F.); gaia.barisione@gmail.com (G.B.);
ulrich.pfeffer@hsanmartino.it (U.P.); gfilaci@unige.it (G.F.); marina.fabbi@hsanmartino.it (M.F.)
2 Azienda Sociosanitaria Ligure 3 (ASL3), Sistema Sanitario Regionale Liguria, 16149 Genova, Italy;
marina.gualco@asl3.liguria.it
3 Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto G. Gaslini|Ospedale Pediatrico Gaslini,
16147 Genova, Italy; patriziaperri@gaslini.org
4 Leiden University Medical Center, 2333ZA Leiden, The Netherlands; m.j.jager@lumc.nl
5 Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool L7 8TX, UK;
s.e.coupland@liverpool.ac.uk
6 Liverpool University Hospitals NHS Foundation Trust, Liverpool L7 8XP, UK
7 Galliera Hospital, 16128 Genova, Italy; carlomosci@icloud.com
8 Centre of Excellence for Biomedical Research and Department of Internal Medicine, University of Genoa,
Via De Toni 14, 16132 Genova, Italy
9 IEO Institute of Oncology Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), 20141 Milan, Italy;
paola.queirolo@ieo.it
* Correspondence: rosaria.gangemi@hsanmartino.it; Tel.: +39-010-555-8376; Fax: +39-010-555-8374
† These authors contributed equally to the work.
Received: 18 May 2020; Accepted: 2 June 2020; Published: 4 June 2020


Abstract: Uveal melanoma (UM) is a rare tumor of the eye that leads to deadly metastases in about
half of the patients. ADAM10 correlates with c-Met expression in UM and high levels of both
molecules are related to the development of metastases. MiR122 and miR144 modulate ADAM10
and c-Met expression in different settings. We hypothesized a potential onco-suppressive role for
miR122 and miR144 through modulation of ADAM10 and c-Met in UM. We analyzed the UM Cancer
Genome Atlas data portal (TCGA) dataset, two other cohorts of primary tumors and five human UM
cell lines for miR122 and miR144 expression by miR microarray, RT-qPCR, Western blotting, miR
transfection and luciferase reporter assay. Our results indicate that miR122 and miR144 are expressed
at low levels in the UM cell lines and in the TCGA UM dataset and were down-modulated in a cohort
of seven UM samples, compared to normal choroid. Both miR122 and miR144 directly targeted
ADAM10 and c-Met. Overexpression of miR122 and miR144 led to reduced expression of ADAM10
and c-Met in the UM cell lines and impaired cell proliferation, migration, cell cycle and shedding of
c-Met ecto-domain. Our results show that miR122 and miR144 display an onco-suppressive role in
UM through ADAM10 and c-Met modulation.
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1. Introduction
Uveal melanoma (UM) is a rare tumor of the eye that gives rise to metastases, especially in the liver,
and is deadly in about one half of cases. Metastases are insensitive to chemotherapy, thereby leading to
a high mortality rate [1–3]. Mutually-exclusive mutations in the GNAQ or GNA11 genes, which encode
signaling proteins associated with G-protein-coupled receptors, are specific drivers of UM [4,5]. Genetic
alterations in primary UM such as monosomy of chromosome 3 and amplification of chromosome 8q are
related to a poor prognosis [6–8]. In addition, inactivating mutations in the BAP1 gene, which is located
on chromosome 3, confer a more aggressive behavior to UM [9–11]. In contrast, mutations in TP53,
BRAF, NRAS, TERT and the CDKN2 genes, which are common in cutaneous melanoma [12,13], are rare
in UM [1]. Besides mutated proteins, high expression of a disintegrin metalloproteinase 10 (ADAM10)
and the tyrosine-kinase receptor c-Met [14–16] has been associated with UM progression. ADAM10 is
a membrane-associated sheddase and has been involved in the proteolysis of several protein substrates
and in tumor spread in several types of cancer [17]. c-Met, the receptor for the hepatocyte growth
factor, mediates tumor cell invasiveness and has also been correlated with oncologic progression [18].
Similarly, we found that expression of ADAM10 and c-Met mRNA was correlated with the development
of metastases in a cohort of 108 primary UM [14]. In addition, active ADAM10 is present in UM
cell lines and the ADAM10 substrate c-Met is shed as ecto-domain into the tissue culture medium.
Indeed, we identified soluble c-Met as a potential biomarker in the sera of metastatic UM patients [19].
The finding that silencing of ADAM10 reduces UM cell invasion further supports an important role for
ADAM10 in UM progression and suggests that ADAM10 may be a potential target for therapeutic
intervention [14].
MicroRNAs (miRs) are a class of small, non-coding, single-stranded RNAs that exert
a post-transcriptional control of gene expression. MiRs preferentially target the 3’-untranslated region
(UTR) of specific sets of mRNA [20] and modulate various biological processes such as proliferation,
cell cycling, differentiation, apoptosis and epithelial-mesenchymal transition. Several miRs have been
associated with ADAM10 and c-Met: previous reports showed that miR122 down-regulates ADAM10
expression in breast cancer [21] and hepatocellular carcinoma [22], while miR144 may play a role
in down-regulating ADAM10 expression in Alzheimer disease [23]. MiR122 is highly expressed in
the normal liver, whereas it is down-regulated in hepatocellular carcinoma [24,25]. In addition, miR122
was reported as a potential onco-suppressor molecule in non-small cell lung cancer [26], gallbladder
carcinoma [27], bladder cancer [28], breast cancer [21] and gastric cancer [29,30]. Moreover, it was
recently reported that miR122 plays a role in hepatocellular carcinoma by directly inhibiting c-Met
expression [31]. Additionally, the expression of miR144 is significantly down-regulated in different
cancers including gastric [32], breast [33], hepatocellular carcinoma [34] and cervical cancer [35]. MiR144
was found to be decreased in UM and restoration of its expression reduced in vitro proliferation
and invasion of UM cells by directly targeting the 3’ UTR of c-Met [36]. Both miR122 and miR144
are involved in the post-transcriptional regulation of ADAM10 and c-Met and their down-regulation
may thus contribute to the high expression of ADAM10 and c-Met seen in UM. Other studies have
also examined miR expression in UM [37–39], but hardly ever addressed the aforementioned two
and functional studies were limited to a few selected miRs identified in cell lines or in limited sample
collections of UM [37]. Here, we investigate the role of miR122 and miR144 in the modulation of
ADAM10 and c-Met expression and their influence on proliferation and invasiveness of UM cell lines.
We show, for the first time, that miR144 and miR122 inhibit both c-Met and ADAM10 expression in
UM cells.
2. Results
2.1. Analysis of miR122 and miR144 Expression in Primary UM Tumors and UM Cell Lines
To address the potential role of miR122 and miR144 in UM, we first analyzed the miR Cancer
Genome Atlas data portal (TCGA) dataset that includes 78 primary UM bearing GNAQ or GNA11
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mutations. MiR144 and miR122 belonged to the lowest (0–30%) percentile of the global miR expression
(Figure 1). Other miRs which could potentially target ADAM10 or c-MET (based on the Miranda target
prediction program), such as miR34a-5p [40], miR34c-5p [41] and miR140-5p [42,43], showed levels of
expression above the 70th percentile (Figure 1). MiR122 and miR144 showed a low expression not only
in the UM TCGA dataset but also in an independent cohort of 19 primary UM that were analyzed
for miR expression by microarray analysis (Figure 2A,B). In addition, miR221 and miR222, which are
known to be expressed in cutaneous melanoma [44], showed a high expression (Figures 1 and 2A,B)
and were then arbitrarily chosen as controls for highly-expressed miRs. No significant differences in
miR122 and miR144 expression were found between metastatic and non-metastatic patients in these
two datasets (miR122 p = 0.66 and miR144 p = 0.77).
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To further corroborate these data, we analyzed the expression of miR122 and miR144 by RT-
qPCR in seven additional primary UM and in normal choroid. U6 small nuclear RNA was used as an 
internal control, while miR221 and miR222 were analyzed as controls. The expression of both miR144 
and miR122 was lower in the primary UM than in the normal choroid (Figure 2C). 
Finally, we analyzed miR122 and miR144 by RT-qPCR in a panel of five UM cell lines (92.1 [45], 
MEL270, OMM2.5 [46], UPMM2 and UPMM3 [47]). OMM2.5 is derived from a liver metastasis from 
the same patient as MEL270 whereas UPMM3 and UPMM2 are derived from primary UM 
monosomic for chromosome 3. MiR122 and miR144 showed a very low expression relative to miR221 
and miR222 in all the cell lines (Figure 2D). 
Taken together, these data indicate a low expression of miR122 and miR144 in both primary UM 
and UM cell lines. 
We next investigated whether there was a difference in c-Met and ADAM10 expression in 
patients with higher miR122 and miR144 compared to patients with lower miR122 and miR144. 
Analysis of the TCGA dataset revealed that low expression (bottom quartile) of both miRs was 
associated with higher expression of both ADAM10 and c-Met. This difference was statistically 
significant for miR144 (Figure S1). 
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To further corroborate these data, we analyzed the expression of miR122 and miR144 by RT-qPCR
in seven additional primary UM and in normal choroid. U6 small nuclear RNA was used as an internal
control, while miR221 and miR222 were analyzed as controls. The expression of both iR144
and iR122 was lower in the pri ary U than in the nor al choroid (Figure 2C).
Finally, e analyzed iR122 and iR144 by RT-qPCR in a panel of five U cell lines (92.1 [45],
EL270, O 2.5 [46], UP 2 and UP 3 [47]). O 2.5 is derived fro a liver etastasis fro
the same patient as MEL270 whereas UPMM3 and UPMM2 are derived from primary UM monosomic
for chro osome 3. MiR122 and miR144 showed a very low expression relative to miR221 and iR222
in all the cell lines (Figure 2D).
Taken together, these data indicate a lo expression of iR122 and iR144 in both pri ary U
and U cell lines.
e next investigated whether there was a difference in c-Met and ADAM10 expression in patients
with higher miR122 and miR144 co pared to patients with lower miR122 and miR144. Analysis of
the TCGA dataset revealed that low expression (bottom quartile) of both miRs was associated with
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higher expression of both ADAM10 and c-Met. This difference was statistically significant for miR144
(Figure S1).
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Figure 2. miR expression in UM patients and cell lines. (A): miR122, miR144, miR221 and miR222
expression in 78 UM from the TCGA: 52 UM were non-metastatic and 26 were metastatic. MiR levels
are expressed as log2 (total_RPM +1) transformed. RPM: reads per million reads. (B): miR122, miR144,
miR221 and miR222 expression in 19 primary UM, of which 5 were metastatic and 14 non-metastatic.
Microarray data show miRNA normalized and log2 transformed of the fluorescence intensity (AU)
(miR122 p = 0.66 and miR144 p = 0.77). (C): miR122, miR144, miR221 and miR222 expression in
normal choroid (NC) and 7 UM using RT-qPCR. Only UM 5 and 6 were non-metastatic. Expression of
miR122 and miR144 was lower in UM samples than in normal choroid. Data are presented as relative
quantification analysis (1/delta Ct) with efficiency-method, compared to the U6 internal control. Values
are the mean ± sd of n = 3 independent RT-qPCR analyses. (D): expression of miR122 and miR144 was
measured in a panel of 5 UM cell lines using RT-qPCR. Data are presented as relative quantification
analysis with efficiency-method, compared to the U6 internal control. Values are the mean ± sd of
n = 3 independent RT-qPCR analyses. Light gray bars = miR221, gray bars = miR222, dark gray
bars = miR122 and black bars = miR144.
2.2. Effect of Synthetic miR122 and miR144 Transfection on ADAM10 and c-Met Expression
To investigate the effects of miR122 and miR144 over-expression in UM cells we transfected
miR-mimics into th 92.1 and UPMM3 cell li es, which represent different types of prima y UM. In eed,
the 92.1 cell line is disomic for chromosome 3 and BAP1 wild-typ , whereas UPMM3 is monosomic
for chromosome-3 and BAP1 mutated [45,47]. RT-qPCR showed an incr ase of the specific miR122
or miR144 in cells transfected with the corresponding miR mimic, i dic ting efficient intracellular
delivery of miR (Figur 3A,B). MiR144 expression increased uch more upon transfection than
miR122, particularly in cell line UP M3. RT-qPCR analysis of ADAM10 and c-Met mRNA expression
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in miR-transfected cells revealed that miR122 inhibits not only mRNA expression of ADAM10, as
found in other cellular models, but also of c-Met (Figure 3C,D) in both UM cell lines. Similarly, miR144
reduced both c-Met and ADAM10 mRNA levels (Figure 3C,D). Indeed, miR122 and miR144 show
complementary sequences with both ADAM10 and c-Met 3’-UTR mRNA (Figure S2).Cancers 2020, 12, x 5 of 17 
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Figure 3. Effects of miR122 and miR144 mimic transfection in UM cell lines. MiR122 (A) and miR144
(B) expression increases in cell lines 92.1 and UPMM3 when transfect d with the corresponding miR
mimic. Increments in miR expression ranged from 800- to 197,000-fold, relative to transf cti control
(irrelevant miR: NC). MiR122 and miR144 mimic transfection inhibit ADAM10 (C) and c-Met (D) mRNA
expression levels, measured by RT-qPCR, in 92.1 and UPMM3 UM cell l nes. Results are presented as
fold change ver us irr levant miR control (NC) of relative qu tification analysis effici ncy-method
based o miR122 and miR144 ta gets compared to the U6 internal control. Values are the mea ± sd of
RT-qPCR analyses. Consistent data were obta ned in two additional experiments (* p < 0.05; ** p < 0.01;
*** p < 0.001).
We next analyzed the effect of mimic miR transfection on protein expression. Western blot analysis
showed that miR122 inhibited ADAM10 and c-Met protein expression in both 92.1 cells, and UPMM3
cells. Furthermore, transfection of miR144 reduced ADAM10 and c-Met protein levels, suggesting that
both miRs can reg late ADAM10 and c-Met protein expression (Figure 4, Figures S3 and S4). Similar
res lts were obtained using OMM2.5 cells, a cell line derived from a UM liver metastasis (Figures S5
and S6).
2.3. Effects of miR122 and miR144 on UM Cell Proliferation and Migration In Vitro
We and others have shown that ADAM10 and c-Met are related to UM invasiveness
and progression [14,15]. Therefore, we explored the possible effects of miR122 or miR144 on UM cell
proliferation and migration.
As shown in Figure 5A, transfection of miR144 reduced proliferation of 92.1 cells measured by
a standard 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) assay, at every time
point, whereas transfection of miR122 decreased 92.1 cell proliferation at 96 h. Overexpression of
miR122 or miR144 mimic reduced UPMM3 cell proliferation at 96 h (Figure S7).
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Figure 4. Western blot analysis of ADAM10 and c-Met expression of miR122 and miR144 transfected
cells. (A): Western blot analysis shows expression of ADAM10 and c-Met proteins in 92.1 and UPMM3
cell lines, upon transfection with mimic miR122, miR144 or an irrelevant miR control (NC). α-tubulin
was used as loading control. Cropped images are obtained from the same blot subsequently probed with
the different antibodies. Molecular weight markers are shown. (B): histograms show the quantification
of band intensity expressed as percentage of the irrelevant miR transfected control (NC). Mean ± sd of
three independent experiments. (* p < 0.05; ** p < 0.01).
Consistent with the pro-invasive role of ADAM10 and c-Met, both miR122 and miR144 inhibited
the migration of 92.1 cells, in response to Hepatocyte Growth Factor (HGF) as chemo-attractant,
in an in vitro trans-well system (Figure 5B). In the UPMM3 cell model, miR144 significantly inhibited
cell migration, while miR122 was less effective (Figure 5C).
Since our previous studies showed that ADAM10 processes surface c-Met and mediates c-Met
ecto-domain shedding [19], we studied the possible effects of miR122 and miR144 mimic transfection
on the release of soluble c-Met in the culture supernatant. As shown in Figure 5D, transfection of
both miR mimics inhibited release of soluble c-Met from the 92.1 cells, while only miR144 significantly
reduced soluble c-Met release in the UPMM3 cell line.
2.4. Effects of miR122 and miR144 on UM Apoptosis and Cell Cycle
We demonstrat d that miR122 and miR144 overexpression reduced UM cell proliferation. Howev r,
MTT assay provides collective effects of cell proliferation and cell death. We therefore tested the possible
role of these miRs in apoptosis and cell cycle modulation. Transfection of miR144 significantly increased
the percentage of apoptosis in 92.1 cells, but not in UPMM3 cells. MiR122 did not affect apoptotic cell
death in both cell lines (Figure 6).
Furthermore, Flow-cytometric analysis showed that miR144 mimic transfection significantly
increased the proportion of cells in the G0/G1 phase and reduced the proportion of cells in the G2/M
phase in comparison with irrelevant miR (Figure 7).
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Figure 5. Effects of miR122 and miR144 mimic transfection on cell proliferation, migration and release
of soluble c-Met. (A): proliferation, detected by a 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium
bromide (MTT) assay, is significantly reduced in 92.1 cells transfected with miR122 and miR144
mimic. Data are expressed as mean ± sd of three different experiments. (B): migration assay shows
a reduction of migrated 92.1 UM cells upon transfection with mimic miR122 or miR144, while migration
of UPMM3 cells (C) is inhibited with mimic miR144. A representative experiment of three is shown.
(D): transfection of mimic miR144 reduces soluble c-Met (sc-Met) levels in conditioned medium
of the 92.1 and UPMM3 UM cell lines while miR122 affects soluble c-Met in 92.1 cells. Data are
representative of three experiments (* p < 0.05; ** p < 0.01; *** p < 0.001).
Figure 6. Cont.
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Figure 6. Flow-cytometric analysis of Annexin-V-PI staining of 92.1 and UPMM3 cells 72h after
transfection with irrelevant miR (NC), miR122 or miR144 mimic. (A): a representative experiment is
shown as dot plot; x-axis: Annexin-V-fluorescein isothiocyanate (FITC) staining, y-axis: Propidium
Iodide (PI) staining. Viable cells take up no stains (lower left quadrant). Cells stained with PI alone are
necrotic (upper left quadrant), cells stained only with Annexin-V-FITC constitute early apoptosis (lower
right quadrant). Cells at final stages of apoptosis display both stains (upper right quadrant). Data are
expressed as percentage of cells in each category. (B): Percentage of early apoptotic and apoptotic cells
from three different experiments were used to calculate the mean ± sd of 92.1 and UPMM3 apoptotic
cells (* p < 0.05).Cancers 2020, 12, x 9 of 17 
 
Figure 7. Cell cycle analysis of UM cells transfected with miRs mimic. Stacked plots are mean of three 
different experiments of 92.1 and UPMM3 cells transfected with irrelevant miR (NC), miR122 or 
miR144 mimic, 72 h after transfection. Standard deviation was below 5% of the mean. Representative 
cell cycle histogram analysis of 92.1 and UPMM3 miRs transfected cells shows a statistically 
significant increase in G0/G1 and decrease in G2/M phases in miR144 transfected cells (* p = 0.03). 
Histograms: x-axis: PI in FL2-Area (DNA content), y-axis: counts. 
2.5. miR122 and miR144 Directly Target 3’UTR Region of Both ADAM10 and c-Met 
To assess whether miR122 and miR144 directly down-regulate ADAM10 and c-Met expression, 
we transfected 92.1 cells with the 3’UTR region of ADAM10 and c-Met cloned in a plasmid vector, 
with luciferase as reporter gene. The luciferase reporter gene assay demonstrated that indeed both 
miR122 and miR144, co-transfected with pGL3-c-Met-3’UTR or pGL3-ADAM10-3’UTR, reduced 
luciferase activity, suggesting that miR122 and miR144 directly target the ADAM10 and c-Met 3’UTR. 
Irrelevant control miR did not affect either pGL3-c-Met-3’UTR or pGL3-ADAM10-3’UTR luciferase 
activity (Figure 8). 
 
Figure 7. Cell cycle analysis of UM cells transfected with miRs mimic. Stacked plots ar mean of three
different experiments of 92.1 and cells transfected with irrelevant miR (NC), miR122 or miR144
Cancers 2020, 12, 1468 9 of 16
mimic, 72 h after transfection. Standard deviation was below 5% of the mean. Representative cell cycle
histogram analysis of 92.1 and UPMM3 miRs transfected cells shows a statistically significant increase
in G0/G1 and decrease in G2/M phases in miR144 transfected cells (* p = 0.03). Histograms: x-axis: PI in
FL2-Area (DNA content), y-axis: counts.
2.5. miR122 and miR144 Directly Target 3’UTR Region of Both ADAM10 and c-Met
To assess whether miR122 and miR144 directly down-regulate ADAM10 and c-Met expression,
we transfected 92.1 cells with the 3’UTR region of ADAM10 and c-Met cloned in a plasmid vector,
with luciferase as reporter gene. The luciferase reporter gene assay demonstrated that indeed both
miR122 and miR144, co-transfected with pGL3-c-Met-3’UTR or pGL3-ADAM10-3’UTR, reduced
luciferase activity, suggesting that miR122 and miR144 directly target the ADAM10 and c-Met 3’UTR.
Irrelevant control miR did not affect either pGL3-c-Met-3’UTR or pGL3-ADAM10-3’UTR luciferase
activity (Figure 8).
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3. Discussion
Metastatic UM still shows a high mortality rate, despite improvements in an efficient treatment of
the primary tumor, in most cases. Hence, the identification and better understanding of the mechanisms
involved in UM dissemination and colonization, together with the identification of new potential
therapeutic targets and tools, is urgent. We have previously shown that both ADAM10 and c-Met are
significantly more expressed in primary UM of patients undergoing liver metastases during follow-up,
compared to those with good prognosis [14]. Interestingly, the expression of these two pro-metastatic
genes is highly correlated [14], suggesting the possibility of a common mechanism regulating their
gene expression. MiRs have been reported to contribute to cancer progression through the modulation
of oncogenes or tumor suppressors. Alteration of several miRs has been described as potentially
pathogenic in UM. Recently, miR181b was shown to be overexpressed in UM and to promote cell cycle
progression in UM cells [48]. On the other hand, other miRs, such as miR9 [49], miR182 [50], miR34b
and miR34c [41], may act as tumor suppressors in UM. In addition, miR144 [36] has been proposed as
a tumor suppressor in UM by targeting the c-Met oncogene.
The present study shows that miR122 and miR144 are expressed at low levels in three different
cohorts of primary UM and also in a panel of UM cells. Low levels of miR122 and miR144 in primary
tumors may contribute to the up-regulation of both pro-metastatic genes ADAM10 and c-Met and may
function as tumor suppressors in this disease. Indeed, we found that low expression of miR122
and miR144 was associated with higher expression of both ADAM10 and c-Met in the UM TCGA
dataset. Furthermore, extremely low levels of expression of miR122 and miR144 were seen in UM
cell lines, which are characterized by elevated levels of ADAM10 and c-Met [14,19]. Transfection of
miR122 and miR144 mimics in 92.1 and UPMM3 cells leads to a reduction of ADAM10 and c-Met
mRNA and protein expression. Consistently with these data, we observed a reduction of proliferation,
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migration and shedding of c-Met in UM miR-transfected cells. In addition, an increase in G0/G1 phase
of the cell cycle was present in both cell lines, while only 92.1 cells showed a concomitant increase of
apoptosis. MiR122 has previously been reported to inhibit growth of hepatocellular carcinoma cells
in vitro and in vivo [22] through the inhibition of different genes, including ADAM10. MiR122 also
targets the 3’UTR of c-Met and its overexpression reduces proliferation and invasion of hepatocellular
carcinoma cell lines [31]. The present work shows that both miR122 and miR144 overexpression
inhibit ADAM10 and c-Met expression and have an anti-migratory and an anti-proliferative effect on
the 92.1 and UPMM3 UM cells, although in the latter the effects are detected only at later time points.
These effects seem to be related to a direct targeting of miR122 and miR144 on the 3’UTR of both
c-Met and ADAM10. The effects of miR122 on ADAM10 and c-Met expression and on the proliferative
and migratory activity of UPMM3 cells was less evident. The lower efficacy of miR122 in the UPMM3
model may relate to the low expression of this miR upon transfection, a finding that was consistently
reproduced in three different transfection experiments. However, this low expression does not
appear to be related to a generally low transfection efficiency of UPMM3 cells, as miR144 is well
expressed upon transfection in these cells. In addition, transfection of fluorescent double strand RNA
oligonucleotides produced comparable results in 92.1, OMM2.5 and UPMM3 cell lines (Figure S8).
Recent findings indicate that endogenous transcripts control specific miRNA levels in mammalian
cells by target-directed miRNA degradation [51]. One may speculate that similar mechanisms of
enhanced degradation may inhibit endogenous or exogenous miR122 expression and activity in UM
cells, particularly in the UPMM3 model. Differences in the functional effects of the two miRs may be
also related to a different efficiency in reducing the targeted genes required to produce a functional
effect, or to other possible additional targets of miR122 and miR144 not considered in this study.
Chromosomal aberrations and BAP1 mutation in UPMM3 cells may influence the onco-suppressive
activity of miR122 and miR144. However, the analysis of miR expression in UM TCGA [6] found
a cluster of miRs associated with monosomy 3 and BAP1 mutation, but miR122/144 are not present in
this cluster, and thus may not be regulated by them.
Finally, the more efficient ability of miR144 to block cell proliferation, stimulate apoptosis and arrest
cell cycle implies an important role for c-Met and ADAM10 in these biological processes in UM. If
miR144 [36] has already been proposed as a tumor suppressor by targeting the c-Met oncogene, its role
on targeting ADAM10 has not been demonstrated until now in UM. The effects of miR144 targeting
both c-Met and ADAM10 are evident in both disomic and monosomic cells, with a prevalent effect on
disomic cell line.
Our data provide further information on the influence of ADAM10 and c-Met in the biology
of UM and clarify some of the molecular mechanisms related to the modulation of miRs targeting
the pro-neoplastic genes ADAM10 and c-Met. The possibility to counteract pro-metastatic activity
of onco-miRs has been investigated by several studies using different types of delivery tools [52,53].
Local delivery of miR122 and miR144 may be considered to restore tumor suppressive activity in UM
and deserves to be further investigated in xenograft animal models of metastatic disease.
4. Methods
4.1. Cell Lines
Human UM cell lines 92.1 [45], MEL270, OMM2.5 [46], UPMM3 and UPMM2 [47] were cultured in
Roswell Park Memorial Institute 1640 medium (Gibco/Life Technologies, Cheshire, UK), supplemented
with 10% fetal bovine serum.
4.2. Patients and Tissue Samples
Normal choroid was obtained from a patient who underwent enucleation due to a basal-cell
epithelioma of the eyelid, which had invaded the orbital cavity, and left the choroid intact. Informed
consent had been obtained, in accordance with the Declaration of Helsinki. Tissue samples
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were obtained from 7 UM patients after enucleation surgery (Comitato Etico Regionale 12-2011,
Emendamento sostanziale n.1 al Protocollo versione 2, 01-10/05/16). Patients and tumor characteristics
have previously been described [14]. Five of the seven patients became metastatic during follow-up.
Another cohort of 19 primary UM derived from 5 metastatic and 14 non-metastatic UM patients
was also used for miRs microarray analysis. For these UM patients, all human samples were provided
by the Health Regulatory Authority (HRA) approved Ocular Oncology Biobank, (NRES REC Ref
16/NW/0380) sponsored by the University of Liverpool and with local approval in place at the Liverpool
University Hospitals NHS Foundation Trust. Seventy-eight patients from TCGA data were analyzed
for miR expression: 52 were non-metastatic and 26 were metastatic. TCGA-UM miR expression dataset
was obtained from UCSC-Xenabrowser (https://xenabrowser.net/) deposited on The Cancer Genome
Atlas data portal (TCGA). Level 3 data were downloaded from TCGA DCC. For each sample, all
isoforms, expression of the same miRNA mature strand, are added together, log2 (total_RPM +1)
transformed and deposited at UCSC into Xena repository, as described on https://xenabrowser.net.
Two of the original 80 patients were excluded from the analysis because they were double mutated for
GNAQ/GNA11. TCGA UM miR expression dataset were unlogged for further analysis.
4.3. RT-qPCR Analyses
Total RNA was extracted from cell lines using a miRNeasy mini kit (Qiagen, Hilden, Germany).
Relative miR expression analysis was performed by RT-qPCR into Roche LightCycler 480 II using
miScript SYBR Green Assay Kit and miScript primer assays (Qiagen).
The miScript primer assay in combination with miScript SYBR Green PCR kit from Qiagen was used
for detection of miR122, 144, 221 and 222. RT-qPCR analysis for ADAM10 and c-Met was performed
as described [14]. Sequences of ADAM10 primers were: GAGGAGTGTACGTGTGCCAGTT, Forward,
GACCACTGAAGTGCCTACTCCA, Reverse; c-Met primers were: TGCACAGTTGGTCCTGCCATGA,
Forward, CAGCCATAGGACCGTATTTCGG, Reverse. Relative quantification of mRNAs was calculated
by the Ct method. Standardization of miRs between samples was obtained by using U6 small nuclear
RNA as an internal control. Sequences of internal control primers were: TGACTTTGTCACAGCCCAAG
Forward, TTCAAACCTCCATGATGCTG Reverse, for B2M, TGCCCTGAGGCACTCTTC Forward,
TGAAGGTAGTTTCGTGGATGC Reverse for ACTB, and GACAATGCAGAGAAGCTGG Forward,
GCAGGAAGACATCATCATCC Reverse for RPII. Standardization of ADAM10 and c-Met genes was
obtained by using -actin, 2-microglobulin and RNA polymerase II as internal control. Values are the mean
± sem of n = 3 independent RT-qPCR analyses.
4.4. Microarray and miRs Expression Analyses
miRCURY LNA probes (miRBase 9.2.) were spotted onto UltraGAPS II slides (Corning) by using
the OmniGrid Accent spotter (GeneMachines, San Carlos, CA, USA) and crosslinked by UV [54].
miRCURY LNA microRNA Array Power labeling kit (Exiqon, Qiagen) was used for miRs labeling
according to the recommendations of the manufacturer. For image acquisition, we used the Axon
Genepix 4000B scanner (Molecular Devices, Sunnyvale, CA, USA) and dedicated software. Intensity
data were preprocessed and normalized, to create a miR expression profile, following standard
procedures as previously described [53]. MiR expression profiles were unlogged for further analysis.
4.5. MTT Assay
Cell proliferation was tested using a 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide
(MTT) assay, (Sigma-Aldrich, Milan, Italy). Optical density (OD) was read on a multiwell scanning
spectrophotometer (ELISA reader BioTek, Savatec, Torino, Italy) at 570 nm.
4.6. MiRs Transfection
MiR mimics were obtained from Qiagen: miR122-5p (cat. no MSY0000421), miR144-3p (cat. no.
MSY0000436). 92.1, UPMM3 and OMM2.5 cell lines were transfected with 100 nM mimic with
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lipofectamine 2000 (Invitrogen/ThermoFisher Scientific, Milan, Italy). AllStars (Qiagen) were used as
negative control. After 48 or 72 h, cells were harvested and used for RNA extraction (mRNeasy Mini
Kit, Qiagen) and real-time PCR analysis of miRs (miScript PCR System, Qiagen) or for Western blot
analysis. Block IT Fluorescent Oligo (Invitrogen,) was also used to test efficiency of transfection by
FACS analysis (FACScan BD, Becton & Dickinson Italy, Milan, Italy).
4.7. Western Blot
The Western blot of cell lysates was performed as previously described [14]. C-Met was detected
by mouse anti-c-Met monoclonal antibody (Cell Signaling, Danvers, MA, USA), while ADAM10 was
detected by rabbit anti-ADAM10 antibody (Abcam, Cambridge, UK). Anti-α-tubulin monoclonal
and anti-GAPDH antibodies (Sigma-Aldrich, Milan, Italy) were also used as loading control.
4.8. Migration Assay
BD BioCoat migration chambers (BD Biosciences Italy, Milan, Italy) were used for migration
assays, as described [55]. Cells were cultured in medium containing 1% FCS for 18 h before the assay.
Recombinant HGF (100 ng/mL; Peprotech Tebu-Bio Italy, Milan, Italy) was added to the bottom
chambers. After 24 h of incubation, migrated cells were fixed and stained with 1% toluidine blue.
Migrating cells were calculated in a minimum of 10 fields, and the mean for each chamber determined.
Experiments were run in triplicate.
4.9. Detection of Soluble c-Met
Soluble c-Met (sc-Met) was measured in the conditioned medium of cell lines upon cell debris
removal by centrifugation at 3000 g for 20 min followed by a second centrifugation at 10,000 g for 30 min.
The level of sc-Met was measured using the Human Total HGFR/c-MET DuoSet IC enzyme-linked
immunosorbent assay (ELISA) kit (R&D Systems, Abingdon, UK) following the manufacturer’s
instructions. Optical density was measured at dual wavelengths of 450 and 540nm (400ATC;
SLTLaboratory Instruments).
4.10. Annexin V-FITC/PI Staining Assay
1 × 105 cells were centrifuged and resuspended in 500 µL of 1X binding buffer. Then Annexin
V-fluorescein isothiocyanate (FITC) and Propidium Iodide (PI) were added accordingly with
the manufacturer’s instructions (eBioscience, ThermoFisher Scientific, Milan, Italy). Flow cytometer
(FACSCalibur; Becton Dickinson, East Rutherford, NJ, USA) was utilized to analyze cell apoptosis
and CellQuest (Becton Dickinson) software was used for data analysis.
4.11. Cell Cycle Analysis
Transfected cells were washed twice in PBS, and permeabilized in cold 70% ethanol and incubated
overnight at 4 ◦C in the dark. After washing twice with PBS, the cells were incubated in 1 mL
of PI staining solution for 30 min at room temperature in the dark. Biological role of irrelevant
miRNA, miR122 and miR144 mimic in UM cells was determined using a flow cytometer (FACSCalibur;
Becton Dickinson). The cell cycle was analyzed by ModFit (Becton Dickinson).
4.12. Luciferase Assay
92.1 cells were seeded in 96-well plates (2 × 104 cells/well) for 24 h. For the reporter gene
assay, cells were co-transfected with pGL3-c-Met-3’UTR (0.5 µg) or pGL3-ADAM10-3’UTR or empty
control plasmid, and miR144 or miR122 mimic or irrelevant miR, in the presence of Renilla plasmid,
by Lipofectamine 2000 (Invitrogen). The firefly and Renilla luciferase activities were measured using
the dual luciferase assay (Promega, Milan, Italy) 48 h after transfection, and expressed as RLU (Relative
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Light Units). Experiments were run in triplicate and results were expressed as mean ± sem of three
independent experiments.
4.13. Statistical Analyses
The paired or unpaired Student’s t-test was used when appropriate. P values are shown as
following: * p < 0.05; ** p < 0.01; *** p < 0.001. Analyses were performed using PRISM 5 (Graph-Pad
Software, San Diego, CA, USA).
4.14. Ethical Approval and Informed Consent
All experimental protocols were approved by institutional and licensing committees as detailed
in the Methods Section 4.2. The methods were carried out in accordance with the relevant guidelines
and institutional regulations, in accordance with the Declaration of Helsinki. Informed consent was
obtained from all participants.
5. Conclusions
In this report, we show for the first time that miR122 and miR144 target directly the 3’UTR of
the pro-invasive molecules ADAM10 and c-Met in UM.
UM patients and cell lines display low levels of these miRs while expressing elevated levels
of ADAM10 and c-Met. These data suggest an oncosuppressive role of these miRs supported by
the in vitro anti-proliferative and anti-migratory activity induced by their overexpression in UM
cells. Further studies are needed to identify mechanisms that modulate the expression of miR122
and miR144 in UM. Xenograft models of UM will be necessary to study the effects of restoration of
these suppressive miR122 and miR144 on UM growth and metastases formation. In vivo studies would
provide the rationale for future therapeutic delivery of tumor suppressive miRs in UM patients.
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